Small Business Innovation Research · Small Business Technology Transfer
Microbiotix, Inc.: SBIR & STTR awards
88 awards worth $78.71M to 1 companies since 2001 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Microbiotix, Inc.'s federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 2 | 1 | $1.58M |
| 2024 | 1 | 0 | $600.0K |
| 2023 | 1 | 0 | $586.7K |
| 2022 | 2 | 0 | $868.8K |
| 2021 | 0 | 2 | $4.44M |
| 2020 | 4 | 0 | $2.38M |
| 2019 | 0 | 3 | $8.94M |
| 2018 | 5 | 0 | $2.98M |
| 2017 | 4 | 0 | $2.20M |
| 2016 | 3 | 0 | $1.79M |
| 2015 | 4 | 2 | $6.14M |
| 2014 | 4 | 1 | $5.34M |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $299.9K | 2025-09-22 |
| Development of well tolerated novel Inhibitors of drug resistant CMV · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $298.6K | 2025-08-08 |
| Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral · topic R42 | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase II | $977.4K | 2025-05-16 |
| Proof of concept experiments for T3SS inhibitors against burn wound infections · topic 41 | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $600.0K | 2024-04-12 |
| Development of antibody drug conjugates as pan-filo antivirals · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $586.7K | 2023-08-21 |
| Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $568.6K | 2022-08-12 |
| Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis · topic 100 | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.2K | 2022-07-01 |
| Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis · topic 100 | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.46M | 2021-06-01 |
| Screening for rAAV transduction enhancers · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.97M | 2021-02-03 |
| Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $585.2K | 2020-09-08 |
| Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $599.4K | 2020-08-01 |
| Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $596.8K | 2020-07-21 |
| Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2019-12-09 |
| Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $3.00M | 2019-08-21 |
| Optimization of novel pyranopyridine efflux pump inhibitors · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.97M | 2019-08-20 |
| Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.97M | 2018-12-14 |
| Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $597.6K | 2018-09-04 |
| Discovery of Zika virus therapeutics using a replicon assay · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $585.0K | 2018-08-13 |
| EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $596.9K | 2018-08-01 |
| Synergistic panfiloviral entry inhibiting antibody drug conjugates · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2018-02-08 |
| Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $595.6K | 2018-01-15 |
| Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy · topic NIA | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $432.7K | 2017-09-01 |
| Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $585.9K | 2017-08-18 |
| Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $594.1K | 2017-06-01 |
| Screening for rAAV transduction enhancers · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $590.6K | 2017-01-27 |
| T SS needle protein inhibitors for the treatment of P aeruginosa infection · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $600.7K | 2016-08-19 |
| Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $584.8K | 2016-08-01 |
| Novel beta lactams as inhibitors of ebola virus infections · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $601.8K | 2016-06-24 |
| GPCR antagonists as anti-Ebola virus entry inhibitors · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $597.1K | 2015-08-01 |
| Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $569.8K | 2015-06-15 |
| Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $576.7K | 2015-03-01 |
| Optimization of novel pyranopyridine efflux pump inhibitors · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.49M | 2015-02-10 |
| Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $576.8K | 2015-02-01 |
| Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.33M | 2015-01-01 |
| Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $590.8K | 2014-07-07 |
| Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.97M | 2014-06-15 |
| Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $583.1K | 2014-05-08 |
| New heterocyclic inhibitors of filoviruses · topic H | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $600.0K | 2014-02-15 |
| New small molecule inhibitors of arenaviruses · topic R | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $598.3K | 2014-02-15 |
| Aminoglycoside potentiators for P. aeruginosa therapy · topic NIAID | Microbiotix, Inc. · Massachusetts | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2013 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.